DE60120936D1 - Behandlung von atemerkrankungen - Google Patents

Behandlung von atemerkrankungen

Info

Publication number
DE60120936D1
DE60120936D1 DE60120936T DE60120936T DE60120936D1 DE 60120936 D1 DE60120936 D1 DE 60120936D1 DE 60120936 T DE60120936 T DE 60120936T DE 60120936 T DE60120936 T DE 60120936T DE 60120936 D1 DE60120936 D1 DE 60120936D1
Authority
DE
Germany
Prior art keywords
treatment
respiratory diseases
glycopyrrolate
dry powder
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60120936T
Other languages
English (en)
Other versions
DE60120936T2 (de
DE60120936T3 (de
Inventor
Robin Mark Bannister
Andrew John Mcglashan Richards
Julian Clive Gilbert
David A Morton
John Staniforth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sosei R&D Ltd
Original Assignee
Arakis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60120936(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arakis Ltd filed Critical Arakis Ltd
Publication of DE60120936D1 publication Critical patent/DE60120936D1/de
Publication of DE60120936T2 publication Critical patent/DE60120936T2/de
Application granted granted Critical
Publication of DE60120936T3 publication Critical patent/DE60120936T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60120936.2T 2000-04-07 2001-04-09 Behandlung von atemerkrankungen Expired - Lifetime DE60120936T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0008660.3A GB0008660D0 (en) 2000-04-07 2000-04-07 The treatment of respiratory diseases
GB0008660 2000-04-07
EP01966751.8A EP1267866B2 (de) 2000-04-07 2001-04-09 Behandlung von atemerkrankungen
PCT/GB2001/001606 WO2001076575A2 (en) 2000-04-07 2001-04-09 The treatment of respiratory diseases

Publications (3)

Publication Number Publication Date
DE60120936D1 true DE60120936D1 (de) 2006-08-03
DE60120936T2 DE60120936T2 (de) 2006-11-02
DE60120936T3 DE60120936T3 (de) 2016-11-17

Family

ID=9889490

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60120936.2T Expired - Lifetime DE60120936T3 (de) 2000-04-07 2001-04-09 Behandlung von atemerkrankungen

Country Status (25)

Country Link
US (3) US7229607B2 (de)
EP (3) EP2193791A1 (de)
JP (1) JP5042426B2 (de)
CN (3) CN1292745C (de)
AT (1) ATE330585T2 (de)
AU (2) AU2004242450B2 (de)
BE (1) BE2013C023I2 (de)
BR (1) BR0109875A (de)
CA (1) CA2405705C (de)
CY (1) CY1105120T1 (de)
DE (1) DE60120936T3 (de)
DK (1) DK1267866T4 (de)
ES (2) ES2266242T5 (de)
GB (1) GB0008660D0 (de)
HK (1) HK1050846B (de)
HU (2) HU230958B1 (de)
IL (2) IL151791A0 (de)
LU (2) LU92166I2 (de)
MX (1) MXPA02009718A (de)
NO (3) NO336142B1 (de)
NZ (2) NZ521476A (de)
PL (1) PL364024A1 (de)
PT (1) PT1267866E (de)
WO (1) WO2001076575A2 (de)
ZA (1) ZA200207420B (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US8580306B2 (en) 2000-11-30 2013-11-12 Vectura Limited Particles for use in a pharmaceutical composition
EP2283818B1 (de) 2000-11-30 2017-08-02 Vectura Limited Herstellungsverfahren für Partikel zur Verwendung in einer Arrzneizusammensetzung
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
KR20040007583A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 연골 질환의 재생치료용 조성물
EP1389468A4 (de) 2001-05-23 2007-01-10 Tanabe Seiyaku Co Zusammensetzungen zur förderung der knochenfrakturheilung
PT3384931T (pt) * 2002-03-01 2019-09-26 Chiesi Farm Spa Formulaçâo superfina de formoterol
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2005014825A2 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
EP1684719B1 (de) * 2003-11-14 2011-10-26 Baxter International Inc. Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen
EP1718336B1 (de) 2004-02-06 2008-06-25 MEDA Pharma GmbH & Co. KG Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen
CN100512813C (zh) * 2004-02-06 2009-07-15 Meda制药有限及两合公司 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合
CN100569235C (zh) * 2004-02-06 2009-12-16 Meda制药有限及两合公司 用于哮喘和copd长期治疗的抗胆碱能药和糖皮质激素的组合
EP1713472A2 (de) * 2004-02-06 2006-10-25 MEDA Pharma GmbH & Co. KG Behandlung von rhinitis mit anticholinergika allein in kombination mit antihistaminen, phosphodiesterase-4-hemmern oder corticosteroiden
JP2007524698A (ja) * 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト シクレソニドとグリコピロニウムとの組合せ物
US7914771B2 (en) * 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CA2568834A1 (en) * 2004-06-29 2006-01-12 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and an anticholinergic
EP1616567A1 (de) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medikamente enthaltend PDE-IV Hemmer und Glycopyrrolatsalzen zur Inhalation
EP1789018A1 (de) * 2004-08-27 2007-05-30 The Dow Chemical Company Verbesserte abgabe von medikamentenzusammensetzungen zur behandlung lebensbedrohender infektionen
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US8623405B2 (en) * 2005-01-28 2014-01-07 Takeda Pharmaceutical Company Limited Finely divided composition containing poorly water soluble substance
CA2595791C (en) 2005-03-16 2013-10-08 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
US7915303B2 (en) * 2005-03-24 2011-03-29 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
CA2631492A1 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
CA2632780C (en) * 2005-12-21 2013-11-12 Meda Pharma Gmbh & Co. Kg Combination of r,r-glycopyrrolate, rolipram, and budesonide for the treatment of inflammatory diseases
GB2434098A (en) * 2005-12-23 2007-07-18 Novartis Ag Process for the preparation of an inhalable dry powder formulation
WO2007109142A2 (en) * 2006-03-17 2007-09-27 Oregon Health & Science University M3 muscarinic receptor antagonists for treating tumors
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
PL2234595T3 (pl) * 2007-12-13 2013-04-30 Novartis Ag Sposób zmniejszania tendencji soli glikopironiowej do agregacji podczas składowania
RU2496479C2 (ru) * 2007-12-13 2013-10-27 Новартис Аг Органические соединения
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2257172A4 (de) 2008-02-26 2013-07-03 Elevation Pharmaceuticals Inc Verfahren und system zur behandlung der chronisch obstruktiver lungenerkrankung durch verabreichung zerstäubter anticholinergika
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
TWI792140B (zh) * 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
AR079726A1 (es) 2009-12-23 2012-02-15 Chiesi Farma Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes
KR20120106753A (ko) 2009-12-23 2012-09-26 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 에어로졸 제제
CN102665678B (zh) 2009-12-23 2014-07-02 奇斯药制品公司 用于copd的联合治疗
UA106098C2 (uk) 2009-12-23 2014-07-25 К'Єзі Фармачеутічі С.П.А. Аерозольна композиція для хозл
CN107096014B (zh) 2010-09-29 2022-07-15 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
PT2739268T (pt) 2011-08-01 2019-01-28 Univ Monash Método e formulação para inalação
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
TR201902687T4 (tr) 2013-03-15 2019-03-21 Pearl Therapeutics Inc İri parçacıklı kristal malzemelerin koşullandırılması için yöntemler ve sistemler.
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
WO2015094927A1 (en) * 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Media milling process for the manufacture of active pharmaceutical ingredients in propellants
SG11201605311UA (en) 2013-12-30 2016-07-28 Chiesi Farma Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
TN2017000077A1 (en) 2014-09-09 2018-07-04 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
RU2699995C2 (ru) * 2014-09-15 2019-09-12 ВЕРОНА ФАРМА ПиэЛСи Жидкая ингаляционная композиция, содержащая rpl 554
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
WO2016170518A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
WO2016204998A1 (en) * 2015-06-15 2016-12-22 Qaam Pharmaceuticals, Llc Glycopyrronium fatty acid salts and methods of making same
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
MX2022004781A (es) 2019-12-02 2022-05-16 Chiesi Farm Spa Lata de acero inoxidable para inhaladores dosificadores presurizados.

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
SA95160463B1 (ar) * 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5690374A (en) * 1996-04-19 1997-11-25 Nor-Easter Enterprises, Inc. Shock-absorbing tool handle
DE59709927D1 (de) * 1996-11-11 2003-05-28 Noe Christian Verwendung eines pharmazeutisch geeigneten Salzes von (3R,2'R)-3-[(Cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidinium zur Herstellung eines Arzneimittels
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
PT954282E (pt) * 1997-01-16 2005-06-30 Massachusetts Inst Technology Preparacao de particulas para inalacao
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
JP2001511160A (ja) * 1997-02-05 2001-08-07 ヤゴ リサーチ アクチェンゲゼルシャフト 医学用エアゾール配合物
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
CA2338753C (en) * 1998-07-24 2006-11-21 Jago Research Ag Medicinal aerosol formulations
DK1102579T3 (da) * 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
AU756852B2 (en) * 1998-11-13 2003-01-23 Jagotec Ag Dry powder for inhalation
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
AU7389300A (en) * 1999-08-02 2001-02-19 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6758795B2 (en) 2000-08-22 2004-07-06 Stephen Barber Adjustable water-fillable exercise weights
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
TWI509631B (zh) 2011-02-25 2015-11-21 Henkel IP & Holding GmbH 用於電子裝置之可燒結銀薄片黏著劑

Also Published As

Publication number Publication date
ATE330585T2 (de) 2006-07-15
AU2004242450A1 (en) 2005-01-20
US8029768B2 (en) 2011-10-04
NZ535284A (en) 2006-04-28
AU8930601A (en) 2001-10-23
DE60120936T2 (de) 2006-11-02
CN101181263A (zh) 2008-05-21
LU92166I2 (fr) 2014-03-13
ES2266242T5 (es) 2016-10-04
ZA200207420B (en) 2003-09-16
LU92393I2 (fr) 2015-11-02
BE2013C023I2 (de) 2020-06-24
AU2010200660B2 (en) 2012-04-19
CN101181263B (zh) 2011-07-06
NO2015024I1 (no) 2015-11-25
JP5042426B2 (ja) 2012-10-03
AU2010200660A1 (en) 2010-03-11
HUS1900056I1 (hu) 2020-02-28
HK1050846B (zh) 2007-01-26
MXPA02009718A (es) 2003-05-27
DK1267866T4 (en) 2016-10-03
PL364024A1 (en) 2004-11-29
US20080220073A1 (en) 2008-09-11
WO2001076575A3 (en) 2002-03-28
CY1105120T1 (el) 2010-03-03
GB0008660D0 (en) 2000-05-31
ES2266242T3 (es) 2007-03-01
CN1422154A (zh) 2003-06-04
US20030068280A1 (en) 2003-04-10
WO2001076575A2 (en) 2001-10-18
NZ521476A (en) 2004-10-29
NO20024708L (no) 2002-10-24
EP1267866B1 (de) 2006-06-21
IL151791A (en) 2015-05-31
EP1267866B2 (de) 2016-07-20
US7229607B2 (en) 2007-06-12
IL151791A0 (en) 2003-04-10
AU776913B2 (en) 2004-09-23
EP1267866A2 (de) 2003-01-02
CN1720995A (zh) 2006-01-18
HK1050846A1 (en) 2003-07-11
NO20024708D0 (no) 2002-10-01
CA2405705C (en) 2011-06-07
EP2193791A1 (de) 2010-06-09
CN1292745C (zh) 2007-01-03
DE60120936T3 (de) 2016-11-17
NO336142B1 (no) 2015-05-26
HU230958B1 (hu) 2019-06-28
US20050019271A1 (en) 2005-01-27
DK1267866T3 (da) 2006-10-23
JP2003530344A (ja) 2003-10-14
AU2004242450B2 (en) 2010-06-03
BR0109875A (pt) 2004-07-20
ES2687751T3 (es) 2018-10-29
NO2015024I2 (no) 2015-11-25
NO2015025I1 (no) 2015-12-07
CA2405705A1 (en) 2001-10-18
PT1267866E (pt) 2006-10-31
HUP0301518A2 (hu) 2003-08-28
EP1449528B1 (de) 2018-08-08
US7368104B2 (en) 2008-05-06
EP1449528A1 (de) 2004-08-25

Similar Documents

Publication Publication Date Title
DE60120936D1 (de) Behandlung von atemerkrankungen
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
MXPA02011311A (es) Composicion novedosa.
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
CL2003002746A1 (es) Compuesto derivado de piridazin-3(2h)-ona sustituida en las posiciones 4,5,6; procedimiento de preparacion de dicho compuesto; compuesto intermediario; composicion farmaceutica; y el uso del compuesto para el tratamiento del asma, enfermedad pulmonar
ME00354B (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
ATE381535T1 (de) Phenethanolaminderivate
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
ATE361287T1 (de) Neue indol-2-on derivate
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
EA200401114A2 (ru) Замещённые гидроксиэтиламины
EA200602016A1 (ru) ПОРОШКОВЫЕ КОМПОЗИЦИИ ДЛЯ ИНГАЛЯЦИИ, СОДЕРЖАЩИЕ ЭНАНТИОМЕРНОЧИСТЫЕ β-АГОНИСТЫ
EA200300152A1 (ru) Фармацевтический препарат сальметерола и пропионата флутиказона
BRPI0417946A (pt) composto, métodos para o tratamento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto
EA200500864A1 (ru) Новый, содержащий тиотропий порошковый препарат для ингаляции
MEP39708A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
DE60202299D1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
HUP0002905A2 (hu) 2-{4-[4-(4,5-Diklór-2-metilimidazol-1-il)butil]1-1piperazinil}-5-fluorpirimidin, előállítása és gyógyászati alkalmazása
SG163512A1 (en) Novel pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion
ECSP034721A (es) Pirido-pirimidinas 6-sustituidas

Legal Events

Date Code Title Description
8363 Opposition against the patent